Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Myeloproliferative Disorders × Hydroxyzine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Vulvar Neoplasms 1 Vulvar Diseases 1 Uterine Cervical Dysplasia 1 Papillomavirus Infections 1 Myeloproliferative Disorders 1 Carcinoma in Situ 1

Interventions

Cyclophosphamide 77 fludarabine phosphate 76 Peripheral Blood Stem Cell Transplantation 59 Mycophenolic Acid 50 Whole-Body Irradiation 49 Busulfan 48 Tacrolimus 46 Antilymphocyte Serum 40 fludarabine 39 Cyclosporine 38 Filgrastim 34 Cytarabine 30 ruxolitinib 29 Methotrexate 29 Melphalan 29 Radiotherapy 22 Etoposide 21 Azacitidine 20 Methylprednisolone 18 Cord Blood Stem Cell Transplantation 15 Sirolimus 14 Decitabine 14 Biopsy 14 thymoglobulin 13 Specimen Handling 13 Granulocyte Colony-Stimulating Factor 13 Alemtuzumab 13 venetoclax 11 Cyclosporins 11 Daunorubicin 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03808805 2025-12-03

APHYPAP

University Hospital, Brest

Phase 3 Completed

Myeloproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon ⚡